FDA grants breakthrough therapy status to MSK ’s Burtomab neuroblastoma therapy
Memorial Sloan Kettering Cancer Center (MSK)-developed Burtomab has received breakthrough therapy designation from the US Food and Drug Administration (FDA) for the treatment of pediatric patients with relapsed or refractory neuroblastoma with centra …
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news
More News: Brain | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Grants | Neuroblastoma | Neurology | Pediatrics | Pharmaceuticals